Buten Matthew
Known title: Chief Financial OfficerCIK: 0001898799
Buten Matthew's purchase track record
Buten Matthew has only 2 open-market purchases with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 10/5/2023 | BHVN | $500K | +75.4% | +116.7% | +20.9% |
| 10/25/2022 | BHVN | $1.50M | +30.0% | -6.9% | +5.5% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| BHVN | ▲ Buy | Option Exercise | 4,250 | $0 | 1/5/2026 | View on chart |
| BHVN | ▼ Sell | Tax Withholding | 2,594 | $26K | 1/5/2026 | View on chart |
| BHVN | ▲ Buy | Option Exercise | 4,250 | $0 | 1/5/2025 | View on chart |
| BHVN | ▼ Sell | Tax Withholding | 2,561 | $99K | 1/5/2025 | View on chart |
| BHVN | ▲ Buy | Open Market | 22,727 | $500K | 10/5/2023 | View on chart |
| BHVN | ▲ Buy | Open Market | 142,857 | $1.5M | 10/25/2022 | View on chart |
| BHVN | ▲ Buy | Option Exercise | 1,550 | $10K | 10/3/2022 | View on chart |
| BHVN | ▲ Buy | Option Exercise | 11,450 | $73K | 10/3/2022 | View on chart |
| BHVN | ▼ Sell | Tax Withholding | 11,042 | $83K | 10/3/2022 | View on chart |
| BHVN | ▼ Sell | Other | 18,750 | $0 | 10/3/2022 | View on chart |
| BHVN | ▼ Sell | Other | 3,088 | $0 | 10/3/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 13, 2026
Biohaven signs $100M deal with Ono for IgG degraders
Biohaven has entered a strategic licensing agreement with Ono Pharma for its IgG degrader technology in Japan and select Asian regions. The deal includes up to $100 million in near-term payments, with $80 million paid upfront. This move expands the company's presence in Asia and supports its lead candidate, BHV-1300, which is currently in Phase 3 trials for Graves' disease.
Biohaven signs $100M deal with Ono for IgG degraders. Biohaven has entered a strategic licensing agreement with Ono Pharma for its IgG degrader technology in Japan and select Asian regions. The deal includes up to $100 million in near-term payments, with $80 million paid upfront. This move expands the company's presence in Asia and supports its lead candidate, BHV-1300, which is currently in Phase 3 trials for Graves' disease.